Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
30.48
+0.13 (0.43%)
At close: Aug 13, 2025, 4:00 PM
29.97
-0.51 (-1.67%)
Pre-market: Aug 14, 2025, 8:11 AM EDT
Amphastar Pharmaceuticals Revenue
Amphastar Pharmaceuticals had revenue of $174.41M in the quarter ending June 30, 2025, a decrease of -4.38%. This brings the company's revenue in the last twelve months to $722.68M, up 1.37% year-over-year. In the year 2024, Amphastar Pharmaceuticals had annual revenue of $731.97M with 13.59% growth.
Revenue (ttm)
$722.68M
Revenue Growth
+1.37%
P/S Ratio
2.02
Revenue / Employee
$356,351
Employees
2,028
Market Cap
1.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 731.97M | 87.57M | 13.59% |
Dec 31, 2023 | 644.40M | 145.41M | 29.14% |
Dec 31, 2022 | 498.99M | 61.22M | 13.98% |
Dec 31, 2021 | 437.77M | 87.92M | 25.13% |
Dec 31, 2020 | 349.85M | 27.49M | 8.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AMPH News
- 1 day ago - Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
- 2 days ago - Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - Accesswire
- 3 days ago - Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - Accesswire
- 6 days ago - Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - Accesswire
- 16 days ago - Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More - Seeking Alpha
- 16 days ago - Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025 - Accesswire
- 4 weeks ago - Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters - Accesswire